Skip to main content
. 2021 Oct 22;70(12):2745–2755. doi: 10.2337/db20-1094

Figure 4.

Figure 4

GRP78 expression can be managed by pharmacological and environmental interventions in adipose tissue. A: GRP78 gene expression in SAT after 6 weeks of metformin treatment at 500 mg twice daily, increased incrementally to 2,000 mg daily at the end of 2 weeks (GSE107894, n = 14). B: GRP78 gene expression in human SAT after 3 months of TZD treatment (GSE13070, n = 40). C: GRP78 gene expression in mouse VAT after 5 weeks of SGLT2i (dapagliflozin) treatment (n = 4). D: GRP78 gene expression in mouse VAT after 3 days of CL316,243 treatment (GSE98132, n = 3). E: GRP78 gene expression in mouse SAT after 11 days of wheel running exercise (GSE68161, n = 7). F: GRP78 gene expression in mouse VAT after 10 weeks of 30% calorie restriction (CR) (GSE60596, n = 3). G: GRP78 gene expression in mouse VAT after 24 h of fasting (GDS4916, n = 5). H: GRP78 gene expression in mouse SAT after 1 week of 30°C thermoneutrality or 4°C cold exposure (GSE13432, n = 3). Data are mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.